<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Cardiol</journal-id><journal-title-group><journal-title>International Journal of Cardiology</journal-title></journal-title-group><issn pub-type="ppub">0167-5273</issn><issn pub-type="epub">1874-1754</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23896537</article-id><article-id pub-id-type="pmc">3919209</article-id><article-id pub-id-type="publisher-id">S0167-5273(13)01249-7</article-id><article-id pub-id-type="doi">10.1016/j.ijcard.2013.06.153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Effect of low doses of long chain <italic>n</italic>-3 polyunsaturated fatty acids on sleep-time heart rate variability: A randomized, controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hall</surname><given-names>Wendy L.</given-names></name><email>wendy.hall@kcl.ac.uk</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Hay</surname><given-names>Georgia</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Maniou</surname><given-names>Zoitsa</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Seed</surname><given-names>Paul T.</given-names></name><xref rid="af0010" ref-type="aff">b</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Chowienczyk</surname><given-names>Philip J.</given-names></name><xref rid="af0015" ref-type="aff">c</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Sanders</surname><given-names>Thomas A.B.</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib></contrib-group><aff id="af0005"><label>a</label>Diabetes and Nutritional Sciences Division, King's College London, London, United Kingdom</aff><aff id="af0010"><label>b</label>Division of Women's Health, King's College London, London, United Kingdom</aff><aff id="af0015"><label>c</label>Cardiovascular Sciences Division, King's College London, London, United Kingdom</aff><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author at: Diabetes and Nutritional Sciences Division, School of Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, England, United Kingdom. Tel.: +&#x000a0;44 20 7848 4171; fax: + 44 20 7848 4273. <email>wendy.hall@kcl.ac.uk</email></corresp><fn id="fn0005"><label>1</label><p>This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>09</day><month>10</month><year>2013</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was
					based on <pub-date pub-type="ppub">.--><pub-date pub-type="ppub"><day>09</day><month>10</month><year>2013</year></pub-date><volume>168</volume><issue>4</issue><fpage>4439</fpage><lpage>4442</lpage><history><date date-type="received"><day>13</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 Elsevier Ireland Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder/><license><license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p></license></permissions><kwd-group><title>Keywords</title><kwd><italic>n</italic>-3 PUFA</kwd><kwd>Electrophysiology</kwd><kwd>Randomized controlled trial</kwd><kwd>Heart rate variability</kwd><kwd>Nutrition</kwd></kwd-group></article-meta></front><body><p>Long chain <italic>n</italic>-3 polyunsaturated fatty acids (<italic>n</italic>-3 PUFA) derived from oily fish, eicosapentaenoic acid (20:5<italic>n</italic>-3, EPA) and particularly docosahexaenoic acid (22:6<italic>n</italic>-3, DHA), can influence cardiac myocyte electrophysiology by modulating ion channels in animal models and in vitro studies <xref rid="bb0005" ref-type="bibr">[1]</xref>. Prospective cohort studies have found a relatively consistent association between the intake of fish and decreased risk of coronary heart disease death. The GISSI trials showed that an additional intake of 0.85&#x000a0;g <italic>n</italic>-3 PUFA decreased coronary heart disease mortality, possibly due to an antiarrhythmic action or augmentation of autonomic tone <xref rid="bb0010 bb0015 bb0020" ref-type="bibr">[2&#x02013;4]</xref>. More recent evidence suggests that <italic>n</italic>-3 PUFA supplementation has little effect on all-cause mortality, cardiac death, sudden death or myocardial infarction when all trials are considered in totality <xref rid="bb0025" ref-type="bibr">[5]</xref>. Measuring heart rate variability (HRV) is an indirect, non-invasive approach to assessing cardiac autonomic function <xref rid="bb0030" ref-type="bibr">[6]</xref>. Low HRV is associated with mortality after a myocardial infarction <xref rid="bb0030 bb0035 bb0040 bb0045" ref-type="bibr">[6&#x02013;9]</xref> and risk of cardiac events in the general population <xref rid="bb0050" ref-type="bibr">[10]</xref>. A meta-analysis concluded that short-term fish oil supplementation may favorably affect certain frequency domain parameters of HRV <xref rid="bb0055" ref-type="bibr">[11]</xref>. The present study examines the effects of low doses of <italic>n</italic>-3 PUFA on HRV, in healthy non-smoking men and women at moderate risk of cardiovascular disease supplemented for 1&#x000a0;y. Here, effects on HRV during sleep-time are investigated, thereby reducing influences from physical activity and emotional/psychological fluctuations.</p><p>The MARINA trial was a single-center dietary intervention study conducted at King's College London, UK between April 2008 and October 2010. Detailed methods and primary outcomes have been reported previously <xref rid="bb0060" ref-type="bibr">[12]</xref>. Ethical approval was obtained from the relevant research ethics committees in the UK (NREC 08/H0802/3) and written informed consent was given by participants. The study was performed in accordance with the principles outlined in the Declaration of Helsinki, and has been registered as a clinical trial at <ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com" id="ir0020">www.controlled-trials.com</ext-link>, unique identifier ISRCTN66664610. Non-smokers aged 45&#x02013;70&#x000a0;years attended a screening visit and those with a medical history of cardiovascular disease (including atrial fibrillation), overall risk of cardiovascular disease in excess of 20% over the next 10&#x000a0;years (<ext-link ext-link-type="uri" xlink:href="http://www.qrisk.org" id="ir0025">www.qrisk.org</ext-link>), cancer (excluding basal cell carcinoma) in the past five years, type 1 diabetes mellitus, uncontrolled type 2 diabetes (fasting plasma glucose&#x000a0;&#x0003e;&#x000a0;7&#x000a0;mmol/L), chronic renal, liver or inflammatory bowel disease, history of substance abuse or alcoholism, pregnancy, weight change of &#x0003e;&#x000a0;3&#x000a0;kg in preceding 2&#x000a0;months, and body mass index &#x0003c;&#x000a0;20 and &#x0003e;&#x000a0;35&#x000a0;kg/m<sup>2</sup> were excluded.</p><p>A randomized, placebo-controlled, double-blind parallel design tested the effects of three dose levels of <italic>n</italic>-3 PUFA versus olive oil placebo (BP specification) for 12&#x000a0;months. The doses chosen were selected to be equivalent to eating none (placebo), 1, 2 or 4 portions of oily fish a week and provided 0, 0.45, 0.9 and 1.8&#x000a0;g of <italic>n</italic>-3 PUFA/d as a purified triacylglycerol with an EPA:DHA ratio of 1.5:1 (Croda Chemicals Europe Ltd, Hull, Yorkshire, UK). Participants were randomly allocated to treatment using minimization to balance age, gender and ethnicity between treatment groups. The treatment associated with the capsule codes were concealed from all study participants, investigators and associated clinical staff.</p><p>On the day prior to each study visit, participants were requested to abstain from strenuous exercise up to the visit and to follow standardized dietary advice. Participants reported to the St Thomas' Hospital clinical research facility between 08:00&#x000a0;h and 10:00&#x000a0;h and an Actiheart monitor was fitted (CamNtech Ltd, Cambridge, UK) <xref rid="bb0065 bb0070" ref-type="bibr">[13,14]</xref> to be worn for 24&#x000a0;h. Following isolation of data during sleep-time, determined by participant records and confirmed by activity data derived from the in-built accelerometer, the data was analyzed using Actiheart 4 software (version 4.0.91) and Kubios HRV software (version 2.0, available online at <ext-link ext-link-type="uri" xlink:href="http://kubios.uku.fi/" id="ir0030">http://kubios.uef.fi/</ext-link>, Biosignal Analysis and Medical Imaging Group, Department of Applied Physics, University of Eastern Finland, Finland) and checked for quality. Time domain parameters included standard deviation of normal-to-normal (NN) intervals (SDNN), standard deviation of the average NN intervals in 5&#x000a0;min segments of the whole recording (SDANN), square root of the mean of the sum of the squares of differences between adjacent NN intervals (RMSSD), the percentage of adjacent NN intervals that differed by more than 50% (pNN50), and triangular index (Ti), the integral of the density distribution (the number of all NN intervals) divided by the maximum of the density distribution. Frequency domain parameters included high frequency (HF), low frequency (LF), and very low frequency (VLF) power, and the ratio of the LF and HF frequency band powers (LF/HF). Some of the measures represent overall variability: including SDNN and Ti <xref rid="bb0030" ref-type="bibr">[6]</xref>. Estimates of short-term components of HRV include RMSSD, pNN50, and HF (0.15 to 0.4&#x000a0;Hz). SDANN and VLF (0.003 to 0.04&#x000a0;Hz) reflect longer-term components, probably a combination of sympathetic and parasympathetic activities. LF power is thought to reflect sympathetic modulation of HR <xref rid="bb0030" ref-type="bibr">[6]</xref>.</p><p>Heart rate variability was defined as a secondary outcome variable of this clinical trial, therefore power calculations for sample size were based on primary endpoints of the trial. Average values on treatment (mean of 6 and 12&#x000a0;months) data were analyzed on an intention to treat basis using analysis of covariance (ANCOVA) with linear trend test, based on a weighted combination (0:1:2:4) of the treatment effects expected in the 4 groups using Stata 11 software (StataCorp LP). Analyses were adjusted for baseline values as well as for age, gender, ethnicity and body mass index. Standard distributional checks were made, and analyses were made following log or other transformation. Following log transformation, geometric means are presented.</p><p>Of 367 participants randomly assigned to treatment, 305 participants completed the HRV recordings (<xref rid="f0005" ref-type="fig">Fig.&#x000a0;1</xref>). After processing and removal of poor quality data, 231 participants remained with usable sleep-time data for all three visits (<xref rid="t0005" ref-type="table">Table&#x000a0;1</xref>). Capsule counts indicated that 209 of the participants consumed &#x02265;&#x000a0;90% of the capsules provided. The proportions of EPA and DHA in erythrocyte lipids increased in a dose-dependent manner indicating long-term compliance to the intervention <xref rid="bb0060" ref-type="bibr">[12]</xref>. There were significant increases in SDANN, Ti and VLF power with <italic>n</italic>-3 PUFA supplementation, but no evidence for a dose-related response (<xref rid="t0010" ref-type="table">Table&#x000a0;2</xref>). There were also significant treatment effects for frequency domain parameter, LF/HF, indicating an increase in sympathetic activity relative to parasympathetic activity. There were no statistically significant effects of treatment for heart rate (data not shown), nor remaining time and frequency domain parameters.</p><p>The present one year intervention study confirmed that HRV was increased during sleep-time by intakes of <italic>n</italic>-3 PUFA achievable through diet, including parameters of longer-phase variability. The relative increase in VLF and SDANN following <italic>n</italic>-3 PUFA has rarely been observed in clinical trials <xref rid="bb0075" ref-type="bibr">[15]</xref>, but is in agreement with observational data from a cohort of older US adults, with VLF appearing to increase at around the level of 1&#x02013;2 servings per week compared to 1&#x02013;3 servings per month or less <xref rid="bb0080" ref-type="bibr">[16]</xref>. Subtle longer-phase fluctuations in heart rate can be more easily discerned during sleep, since greater amplitude oscillations in HRV in response to sympathetic input arising from activity and psychological influences are absent. Indeed, during waking periods, SDANN is powerfully determined by physical activity, or probably the metabolic and thermoregulatory changes associated with physical activity <xref rid="bb0085" ref-type="bibr">[17]</xref>, and therefore it would be of interest to test whether increases in this longer-phase variability could be detected during a 24&#x000a0;h ambulatory HRV measurement period.</p><p>Low VLF power is a strong prognostic indicator of mortality after a myocardial infarction, particularly arrhythmic death <xref rid="bb0035" ref-type="bibr">[7]</xref>, and reduced SDANN has been associated with increased mortality following a myocardial infarction <xref rid="bb0040" ref-type="bibr">[8]</xref>. Less is known about the prognostic utility of these parameters in individuals without pre-existing CHD <xref rid="bb0050" ref-type="bibr">[10]</xref>. The VLF band of the power spectrum may represent longer-phase periodic physiological shifts arising from hormonal changes, the renin&#x02013;angiotensin system and thermoregulation <xref rid="bb0090" ref-type="bibr">[18]</xref>.</p><p>Limitations of this study include the loss of data from 81 completing participants due to poor quality HRV recordings, and the fact that power calculations were not performed for any of the HRV parameters addressed in the analysis. However, strengths of the study include the use of a dose range of <italic>n</italic>-3 PUFA consistent with the range found in human diets, the comparatively long duration of dietary intervention, and evidence of good compliance. These data suggest that intakes of <italic>n</italic>-3 PUFA equivalent to one serving of oily fish a week alter some longer-term parameters of HRV in non-smoking healthy adults at mild to moderately increased risk of cardiovascular disease during sleep-time.</p><p>Financial support was received from the <funding-source id="gts0005">Food Standards Agency (UK)</funding-source> and the <funding-source id="gts0010">Department of Health (UK)</funding-source>, project code N02041. The authors acknowledge support from the Department of Health (UK) via the <funding-source id="gts0015">National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre</funding-source> award to <funding-source id="gts0020">Guy's and St Thomas' NHS Foundation Trust</funding-source> in partnership with <funding-source id="gts0025">King's College London</funding-source> and <funding-source id="gts0030">King's College Hospital NHS Foundation Trust</funding-source>.</p><p>The authors have no financial or commercial interest in any company or organization sponsoring the research. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health, UK.</p><p>We would also like to acknowledge CRODA Europe Ltd (Hull, East Yorkshire, UK) for formulating and supplying the oils for the intervention. We are grateful to Professor Malcolm Law, Dr Lee Hooper and Professor Kennedy Cruickshank for agreeing to be on the Data Monitoring Committee. The assistance of Paula Darroch, manager of the St Thomas' Hospital Clinical Research Centre, Fiona Lewis, Robert Gray, Dr Roy Sherwood, and Laura O'Sullivan is gratefully acknowledged. We are particularly grateful to the participants of the study.</p></body><back><ref-list><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Adkins</surname><given-names>Y.</given-names></name><name><surname>Kelley</surname><given-names>D.S.</given-names></name></person-group><article-title>Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids</article-title><source>J Nutr Biochem</source><volume>21</volume><year>2010</year><fpage>781</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">20382009</pub-id></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Marchioli</surname><given-names>R.</given-names></name><name><surname>Barzi</surname><given-names>F.</given-names></name><name><surname>Bomba</surname><given-names>E.</given-names></name><name><surname>Chieffo</surname><given-names>C.</given-names></name><name><surname>Di Gregorio</surname><given-names>D.</given-names></name><name><surname>Di Mascio</surname><given-names>R.</given-names></name></person-group><article-title>Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione</article-title><source>Circulation</source><volume>105</volume><year>2002</year><fpage>1897</fpage><lpage>1903</lpage><pub-id pub-id-type="pmid">11997274</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Tavazzi</surname><given-names>L.</given-names></name><name><surname>Maggioni</surname><given-names>A.P.</given-names></name><name><surname>Marchioli</surname><given-names>R.</given-names></name><name><surname>Barlera</surname><given-names>S.</given-names></name><name><surname>Franzosi</surname><given-names>M.G.</given-names></name><name><surname>Latini</surname><given-names>R.</given-names></name></person-group><article-title>Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet</source><volume>372</volume><year>2008</year><fpage>1223</fpage><lpage>1230</lpage><pub-id pub-id-type="pmid">18757090</pub-id></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Mozaffarian</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>J.H.</given-names></name></person-group><article-title>Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events</article-title><source>J Am Coll Cardiol</source><volume>58</volume><year>2011</year><fpage>2047</fpage><lpage>2067</lpage><pub-id pub-id-type="pmid">22051327</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Rizos</surname><given-names>E.C.</given-names></name><name><surname>Ntzani</surname><given-names>E.E.</given-names></name><name><surname>Bika</surname><given-names>E.</given-names></name><name><surname>Kostapanos</surname><given-names>M.S.</given-names></name><name><surname>Elisaf</surname><given-names>M.S.</given-names></name></person-group><article-title>Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis</article-title><source>JAMA</source><volume>308</volume><year>2012</year><fpage>1024</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">22968891</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="journal" id="rf0090"><article-title>Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology</article-title><source>Eur Heart J</source><volume>17</volume><year>1996</year><fpage>354</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">8737210</pub-id></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Bigger</surname><given-names>J.T.</given-names></name><name><surname>Fleiss</surname><given-names>J.L.</given-names></name><name><surname>Steinman</surname><given-names>R.C.</given-names></name><name><surname>Rolnitzky</surname><given-names>L.M.</given-names></name><name><surname>Kleiger</surname><given-names>R.E.</given-names></name><name><surname>Rottman</surname><given-names>J.N.</given-names></name></person-group><article-title>Frequency domain measures of heart period variability and mortality after myocardial infarction</article-title><source>Circulation</source><volume>85</volume><year>1992</year><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">1728446</pub-id></element-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Vaishnav</surname><given-names>S.</given-names></name><name><surname>Stevenson</surname><given-names>R.</given-names></name><name><surname>Marchant</surname><given-names>B.</given-names></name><name><surname>Lagi</surname><given-names>K.</given-names></name><name><surname>Ranjadayalan</surname><given-names>K.</given-names></name><name><surname>Timmis</surname><given-names>A.D.</given-names></name></person-group><article-title>Relation between heart rate variability early after acute myocardial infarction and long-term mortality</article-title><source>Am J Cardiol</source><volume>73</volume><year>1994</year><fpage>653</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">8166060</pub-id></element-citation></ref><ref id="bb0045"><label>9</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Quintana</surname><given-names>M.</given-names></name><name><surname>Storck</surname><given-names>N.</given-names></name><name><surname>Lindblad</surname><given-names>L.E.</given-names></name><name><surname>Lindvall</surname><given-names>K.</given-names></name><name><surname>Ericson</surname><given-names>M.</given-names></name></person-group><article-title>Heart rate variability as a means of assessing prognosis after acute myocardial infarction. A 3-year follow-up study</article-title><source>Eur Heart J</source><volume>18</volume><year>1997</year><fpage>789</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">9152649</pub-id></element-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Tsuji</surname><given-names>H.</given-names></name><name><surname>Larson</surname><given-names>M.G.</given-names></name><name><surname>Venditti</surname><given-names>F.J.</given-names><suffix>Jr.</suffix></name><name><surname>Manders</surname><given-names>E.S.</given-names></name><name><surname>Evans</surname><given-names>J.C.</given-names></name><name><surname>Feldman</surname><given-names>C.L.</given-names></name></person-group><article-title>Impact of reduced heart rate variability on risk for cardiac events</article-title><source>The Framingham Heart Stud Circ</source><volume>94</volume><year>1996</year><fpage>2850</fpage><lpage>2855</lpage></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Xin</surname><given-names>W.</given-names></name><name><surname>Wei</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.Y.</given-names></name></person-group><article-title>Short-term effects of fish-oil supplementation on heart rate variability in humans: a meta-analysis of randomized controlled trials</article-title><source>Am J Clin Nutr</source><volume>97</volume><year>2013</year><fpage>926</fpage><lpage>935</lpage><pub-id pub-id-type="pmid">23515005</pub-id></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>T.A.</given-names></name><name><surname>Hall</surname><given-names>W.L.</given-names></name><name><surname>Maniou</surname><given-names>Z.</given-names></name><name><surname>Lewis</surname><given-names>F.</given-names></name><name><surname>Seed</surname><given-names>P.T.</given-names></name><name><surname>Chowienczyk</surname><given-names>P.J.</given-names></name></person-group><article-title>Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial</article-title><source>Am J Clin Nutr</source><volume>94</volume><year>2011</year><fpage>973</fpage><lpage>980</lpage><pub-id pub-id-type="pmid">21865334</pub-id></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Brage</surname><given-names>S.</given-names></name><name><surname>Brage</surname><given-names>N.</given-names></name><name><surname>Franks</surname><given-names>P.W.</given-names></name><name><surname>Ekelund</surname><given-names>U.</given-names></name><name><surname>Wareham</surname><given-names>N.J.</given-names></name></person-group><article-title>Reliability and validity of the combined heart rate and movement sensor Actiheart</article-title><source>Eur J Clin Nutr</source><volume>59</volume><year>2005</year><fpage>561</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">15714212</pub-id></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Kristiansen</surname><given-names>J.</given-names></name><name><surname>Korshoj</surname><given-names>M.</given-names></name><name><surname>Skotte</surname><given-names>J.H.</given-names></name><name><surname>Jespersen</surname><given-names>T.</given-names></name><name><surname>Sogaard</surname><given-names>K.</given-names></name><name><surname>Mortensen</surname><given-names>O.S.</given-names></name></person-group><article-title>Comparison of two systems for long-term heart rate variability monitoring in free-living conditions&#x02014;a pilot study</article-title><source>Biomed Eng Online</source><volume>10</volume><year>2011</year><fpage>27</fpage><pub-id pub-id-type="pmid">21481282</pub-id></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Carney</surname><given-names>R.M.</given-names></name><name><surname>Freedland</surname><given-names>K.E.</given-names></name><name><surname>Stein</surname><given-names>P.K.</given-names></name><name><surname>Steinmeyer</surname><given-names>B.C.</given-names></name><name><surname>Harris</surname><given-names>W.S.</given-names></name><name><surname>Rubin</surname><given-names>E.H.</given-names></name></person-group><article-title>Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease</article-title><source>Psychosom Med</source><volume>72</volume><year>2010</year><fpage>748</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">20716712</pub-id></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Mozaffarian</surname><given-names>D.</given-names></name><name><surname>Stein</surname><given-names>P.K.</given-names></name><name><surname>Prineas</surname><given-names>R.J.</given-names></name><name><surname>Siscovick</surname><given-names>D.S.</given-names></name></person-group><article-title>Dietary fish and omega-3 fatty acid consumption and heart rate variability in US adults</article-title><source>Circulation</source><volume>117</volume><year>2008</year><fpage>1130</fpage><lpage>1137</lpage><pub-id pub-id-type="pmid">18285566</pub-id></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Roach</surname><given-names>D.</given-names></name><name><surname>Wilson</surname><given-names>W.</given-names></name><name><surname>Ritchie</surname><given-names>D.</given-names></name><name><surname>Sheldon</surname><given-names>R.</given-names></name></person-group><article-title>Dissection of long-range heart rate variability: controlled induction of prognostic measures by activity in the laboratory</article-title><source>J Am Coll Cardiol</source><volume>43</volume><year>2004</year><fpage>2271</fpage><lpage>2277</lpage><pub-id pub-id-type="pmid">15193692</pub-id></element-citation></ref><ref id="bb0090"><label>18</label><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Togo</surname><given-names>F.</given-names></name><name><surname>Kiyono</surname><given-names>K.</given-names></name><name><surname>Struzik</surname><given-names>Z.R.</given-names></name><name><surname>Yamamoto</surname><given-names>Y.</given-names></name></person-group><article-title>Unique very low-frequency heart rate variability during deep sleep in humans</article-title><source>IEEE Trans Biomed Eng</source><volume>53</volume><year>2006</year><fpage>28</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">16402600</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f0005"><label>Fig.&#x000a0;1</label><caption><p>Consort diagram of the flow of participants throughout the study and HRV data analysis.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap id="t0005" position="float"><label>Table&#x000a0;1</label><caption><p>Details of the study participants at run-in by randomly assigned treatment group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;52)</th><th align="left">0.45&#x000a0;g/d (<italic>n</italic>&#x000a0;=&#x000a0;64)</th><th align="left">0.9&#x000a0;g/d (<italic>n</italic>&#x000a0;=&#x000a0;59)</th><th align="left">1.8&#x000a0;g/d (<italic>n</italic>&#x000a0;=&#x000a0;56)</th><th align="left"><italic>P</italic> value<xref rid="tf0020" ref-type="table-fn">c</xref></th></tr></thead><tbody><tr><td align="left">Age (years)<xref rid="tf0010" ref-type="table-fn">a</xref></td><td align="char">56 (54,58)</td><td align="char">55 (53,57)</td><td align="char">55 (54,57)</td><td align="char">54 (52,55)</td><td align="char">0.455</td></tr><tr><td align="left">Sex<xref rid="tf0015" ref-type="table-fn">b</xref></td><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x000a0;Male</td><td align="char">21 (40.4%)</td><td align="char">28 (43.8%)</td><td align="char">22 (37.3%)</td><td align="char">23 (41.1%)</td><td rowspan="2" align="char">0.911</td></tr><tr><td align="left">&#x000a0;Female</td><td align="char">31 (59.6%)</td><td align="char">36 (66.2%)</td><td align="char">37 (62.7%)</td><td align="char">33 (58.9%)</td></tr><tr><td align="left">Ethnicity<xref rid="tf0015" ref-type="table-fn">b</xref></td><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x000a0;White</td><td align="char">44 (84.6%)</td><td align="char">50 (78.1%)</td><td align="char">49 (83.1%)</td><td align="char">48 (85.7%)</td><td rowspan="5" align="char">0.377</td></tr><tr><td align="left">&#x000a0;Black</td><td align="char">2 (3.8%)</td><td align="char">2 (3.1%)</td><td align="char">0 (0.0%)</td><td align="char">3 (5.4%)</td></tr><tr><td align="left">&#x000a0;Asian</td><td align="char">2 (3.8%)</td><td align="char">5 (7.8%)</td><td align="char">5 (8.5%)</td><td align="char">0 (0.0%)</td></tr><tr><td align="left">&#x000a0;Far Eastern</td><td align="char">3 (5.8%)</td><td align="char">4 (6.3%)</td><td align="char">4 (6.8%)</td><td align="char">1 (1.8%)</td></tr><tr><td align="left">&#x000a0;Other</td><td align="char">1 (1.9%)</td><td align="char">3 (4.7%)</td><td align="char">1 (1.7%)</td><td align="char">4 (7.1%)</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)<xref rid="tf0010" ref-type="table-fn">a</xref></td><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x000a0;Women</td><td align="char">26 (24,27)</td><td align="char">25 (24,27)</td><td align="char">26 (25,28)</td><td align="char">25 (24,26)</td><td align="char">0.387</td></tr><tr><td align="left">&#x000a0;Men</td><td align="char">26 (25,28)</td><td align="char">26 (25,27)</td><td align="char">26 (25,28)</td><td align="char">25 (24,27)</td><td align="char">0.686</td></tr><tr><td align="left">SBP (mm&#x000a0;Hg)<xref rid="tf0010" ref-type="table-fn">a</xref></td><td align="char">121 (116,125)</td><td align="char">121 (117,124)</td><td align="char">123 (120,127)</td><td align="char">119 (115,123)</td><td align="char">0.513</td></tr><tr><td align="left">DBP (mm&#x000a0;Hg)<xref rid="tf0010" ref-type="table-fn">a</xref></td><td align="char">76 (73,78)</td><td align="char">76 (74,79)</td><td align="char">78 (76,81)</td><td align="char">76 (73,78)</td><td align="char">0.293</td></tr><tr><td align="left">Glucose (mmol/L)<xref rid="tf0010" ref-type="table-fn">a</xref></td><td align="char">5.4 (5.3,5.6)</td><td align="char">5.5 (5.3,5.8)</td><td align="char">5.4 (5.2,5.5)</td><td align="char">5.3 (5.1,5.4)</td><td align="char">0.160</td></tr><tr><td align="left">TC:HDL<xref rid="tf0010" ref-type="table-fn">a</xref></td><td align="char">3.7 (3.4,3.9)</td><td align="char">3.7 (3.5,4.0)</td><td align="char">3.4 (3.2,3.6)</td><td align="char">3.5 (3.2,3.8)</td><td align="char">0.127</td></tr><tr><td align="left">Erythrocyte EPA (%)</td><td align="char">1.29 (1.17,1.40)</td><td align="char">1.26 (1.14,1.38)</td><td align="char">1.32 (1.18,1.46)</td><td align="char">1.27 (1.14,1.40)</td><td align="char">0.917</td></tr><tr><td align="left">Erythrocyte DHA (%)</td><td align="char">6.51 (6.08,6.94)</td><td align="char">6.50 (6.16,6.84)</td><td align="char">6.27 (5.88,6.65)</td><td align="char">6.35 (5.94,6.76)</td><td align="char">0.771</td></tr></tbody></table><table-wrap-foot><fn><p>SBP, seated systolic blood pressure; DBP, seated diastolic blood pressure; TC:HDL, total cholesterol to high density lipoprotein cholesterol ratio; Asian&#x000a0;=&#x000a0;South Asian, SE Asian &#x00026; Middle Eastern.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0010"><label>a</label><p>Mean, 95% confidence intervals in parentheses.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0015"><label>b</label><p><italic>n</italic> (%).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0020"><label>c</label><p><italic>P</italic> values are given for comparisons between treatment groups by one-way ANOVA for age, BMI, BP, fasting glucose, TC:HDL ratio and erythrocyte membrane <italic>n</italic>-3 PUFA, and by chi-square test for distributions of sexes and ethnic groups between treatment groups.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0010" position="float"><label>Table&#x000a0;2</label><caption><p>Interbeat interval and time and frequency domain heart rate variability indices at baseline and following treatment with increasing doses of (<italic>n</italic>-3) long chain polyunsaturated fatty acids versus placebo. Treatment effects are corrected for age, sex, ethnicity, BMI, and the pre-treatment value of the measure.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th align="left">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;52)</th><th align="left">0.45&#x000a0;g/d (<italic>n</italic>&#x000a0;=&#x000a0;64)</th><th align="left">0.9&#x000a0;g/d (<italic>n</italic>&#x000a0;=&#x000a0;59)</th><th align="left">1.8&#x000a0;g/d (<italic>n</italic>&#x000a0;=&#x000a0;56)</th><th align="left"><italic>P</italic> value<xref rid="tf0025" ref-type="table-fn">a</xref></th></tr></thead><tbody><tr><td rowspan="3" align="left">IBI (ms)</td><td align="left">Baseline<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">924 (862, 990)</td><td align="char">966 (934, 1008)</td><td align="char">903 (836, 976)</td><td align="char">971 (936, 1008)</td><td/></tr><tr><td align="left">Rx<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">955 (920, 992)</td><td align="char">965 (934, 996)</td><td align="char">918 (884, 953)</td><td align="char">973 (940, 1008)</td><td/></tr><tr><td align="left">Treatment effect<xref rid="tf0035" ref-type="table-fn">c</xref></td><td align="left">1.000 [Reference]</td><td align="char">1.000 (0.952, 1.049)</td><td align="char">0.962 (0.916, 1.010)</td><td align="char">1.000 (0.951, 1.052)</td><td align="char">0.602</td></tr><tr><td rowspan="3" align="left">SDNN (ms)</td><td align="left">Baseline<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">95.0 (86.8, 103.9)</td><td align="char">92.8 (85.7, 100.5)</td><td align="char">95.1 (85.7, 105.6)</td><td align="char">92.4 (85.4, 100.0)</td><td/></tr><tr><td align="left">Rx<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">87.7 (81.4, 94.6)</td><td align="char">96.1 (89.5, 103.2)</td><td align="char">90.3 (85.1, 95.8)</td><td align="char">94.0 (87.3, 101.3)</td><td/></tr><tr><td align="left">Treatment effect<xref rid="tf0035" ref-type="table-fn">c</xref></td><td align="left">1.000 [Reference]</td><td align="char">1.104 (1.022, 1.193)</td><td align="char">1.034 (0.955, 1.119)</td><td align="char">1.072 (0.988, 1.162)</td><td align="char">0.069</td></tr><tr><td rowspan="3" align="left">SDANN (ms)</td><td align="left">Baseline<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">76.3 (68.0, 85.6)</td><td align="char">72.9 (64.4, 82.5)</td><td align="char">74.0 (65.2, 83.9)</td><td align="char">65.1 (59.2, 71.4)</td><td/></tr><tr><td align="left">Rx<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">67.2 (61.0, 74.0)</td><td align="char">74.4 (67.9, 81.6)</td><td align="char">74.6 (68.8, 80.9)</td><td align="char">74.2 (66.7, 82.4)</td><td/></tr><tr><td align="left">Treatment effect<xref rid="tf0035" ref-type="table-fn">c</xref></td><td align="left">1.000 [Reference]</td><td align="char">1.117 (0.992, 1.258)</td><td align="char">1.123 (0.995, 1.268)</td><td align="char">1.141 (1.007, 1.293)</td><td align="char">0.020</td></tr><tr><td rowspan="3" align="left">RMSSD (ms)</td><td align="left">Baseline<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">33.8 (30.4, 37.5)</td><td align="char">36.0 (32.0, 40.5)</td><td align="char">35.4 (31.6, 40.0)</td><td align="char">37.6 (32.9, 43.0)</td><td/></tr><tr><td align="left">Rx<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">36.5 (32.7, 40.6)</td><td align="char">36.4 (32.9, 40.3)</td><td align="char">33.6 (30.6, 36.8)</td><td align="char">36.8 (33.2, 40.7)</td><td/></tr><tr><td align="left">Treatment effect<xref rid="tf0035" ref-type="table-fn">c</xref></td><td align="left">1.000 [Reference]</td><td align="char">0.964 (0.871, 1.066)</td><td align="char">0.894 (0.807, 0.991)</td><td align="char">0.947 (0.852, 1.052)</td><td align="char">0.129</td></tr><tr><td rowspan="3" align="left">Ti</td><td align="left">Baseline<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">21.6 (19.4, 24.1)</td><td align="char">20.9 (19.3, 22.7)</td><td align="char">21.1 (19.4, 23.1)</td><td align="char">21.1 (19.2, 23.2)</td><td/></tr><tr><td align="left">Rx<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">20.0 (18.5, 21.6)</td><td align="char">22.3 (20.9, 23.8)</td><td align="char">21.3 (19.9, 22.7)</td><td align="char">22.0 (20.4, 23.8)</td><td/></tr><tr><td align="left">Treatment effect<xref rid="tf0035" ref-type="table-fn">c</xref></td><td align="left">1.000 [Reference]</td><td align="char">1.127 (1.037, 1.224)</td><td align="char">1.075 (0.988, 1.169)</td><td align="char">1.098 (1.008, 1.196)</td><td align="char">0.014</td></tr><tr><td rowspan="3" align="left">HF (ms<sup>2</sup>)</td><td align="left">Baseline <xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">324 (260, 404)</td><td align="char">330 (261, 417)</td><td align="char">347 (274, 440)</td><td align="char">350 (270, 452)</td><td/></tr><tr><td align="left">Rx<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">347 (275, 439)</td><td align="char">337 (271, 419)</td><td align="char">302 (248, 369)</td><td align="char">326 (268, 398)</td><td/></tr><tr><td align="left">Treatment effect<xref rid="tf0035" ref-type="table-fn">c</xref></td><td align="left">1.000 [Reference]</td><td align="char">0.962 (0.784, 1.180)</td><td align="char">0.829 (0.673, 1.022)</td><td align="char">0.902 (0.729, 1.117)</td><td align="char">0.198</td></tr><tr><td rowspan="3" align="left">LF (ms<sup>2</sup>)</td><td align="left">Baseline<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">696 (559, 867)</td><td align="char">731 (591, 903)</td><td align="char">767 (630, 934)</td><td align="char">790 (641, 973)</td><td/></tr><tr><td align="left">Rx<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">637 (500, 811)</td><td align="char">702 (576, 856)</td><td align="char">675 (564, 809)</td><td align="char">752 (610, 926)</td><td/></tr><tr><td align="left">Treatment effect<xref rid="tf0035" ref-type="table-fn">c</xref></td><td align="left">1.000 [Reference]</td><td align="char">1.053 (0.903, 1.229)</td><td align="char">0.989 (0.845, 1.157)</td><td align="char">1.048 (0.892, 1.231)</td><td align="char">0.650</td></tr><tr><td rowspan="3" align="left">LF/HF</td><td align="left">Baseline<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">2.15 (1.81, 2.55)</td><td align="char">2.21 (1.87, 2.61)</td><td align="char">2.21 (1.85, 2.64)</td><td align="char">2.26 (1.87, 2.74)</td><td/></tr><tr><td align="left">Rx<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">1.83 (1.52, 2.20)</td><td align="char">2.08 (1.76, 2.47)</td><td align="char">2.23 (1.92, 2.61)</td><td align="char">2.30 (1.92, 2.77)</td><td/></tr><tr><td align="left">Treatment effect<xref rid="tf0035" ref-type="table-fn">c</xref></td><td align="left">1.000 [Reference]</td><td align="char">1.097 (0.946, 1.271)</td><td align="char">1.212 (1.042, 1.409)</td><td align="char">1.163 (0.997, 1.357)</td><td align="char">0.020</td></tr><tr><td rowspan="3" align="left">VLF (ms<sup>2</sup>)</td><td align="left">Baseline<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">5363 (4493, 6403)</td><td align="char">5021 (4297, 5866)</td><td align="char">4962 (4271, 5765)</td><td align="char">4870 (4198, 5649)</td><td/></tr><tr><td align="left">Rx<xref rid="tf0030" ref-type="table-fn">b</xref></td><td align="left">4444 (3844, 5138)</td><td align="char">5492 (4768, 6326)</td><td align="char">4857 (4334, 5443)</td><td align="char">5141 (4447, 5944)</td><td/></tr><tr><td align="left">Treatment effect<xref rid="tf0035" ref-type="table-fn">c</xref></td><td align="left">1.000 [Reference]</td><td align="char">1.271 (1.105, 1.461)</td><td align="char">1.149 (0.997, 1.325)</td><td align="char">1.199 (1.036, 1.387)</td><td align="char">0.005</td></tr></tbody></table><table-wrap-foot><fn><p>IBI, interbeat interval (also known as RR interval), the time interval between R spikes of the QRS complex; SDNN, standard deviation of all NN intervals (normal-to-normal intervals, similar to R&#x02013;R, but on normalized IBI data); SDANN, standard deviation of the averaged NN intervals, calculated from 5&#x000a0;min epochs; RMSSD, the square root of the mean of the sum of squares of differences between adjacent NN intervals; Ti, total number of all NN intervals divided by the height of the histogram of all NN intervals with bins of 7.8125&#x000a0;ms. HF, high frequency power, or variation; LF, low frequency power; LF/HF, ratio of LF to HF power; VLF, very low frequency power.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0025"><label>a</label><p>Significance tests investigate a linear trend with dose.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0030"><label>b</label><p>Values are geometric means; 95% CI in parentheses. Data were log-transformed before analysis.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0035"><label>c</label><p>Treatment effect versus placebo (average of change following each treatment divided by change on placebo at 6 and 12&#x000a0;months), based on estimated marginal means (adjusted for covariates: age, sex, ethnicity, BMI, and the value at baseline).</p></fn></table-wrap-foot></table-wrap></floats-group></article>